Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib vs Imatinib in newly diagnosed Ph+ CML-CP (China)
CTR20182503Phase 3Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of radotinib in chronic myelogenous leukemia (CML), sponsored by Il-Yang Pharmaceutical. Started Jan 2019; status: completed.
02
Drugs
radotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20182503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182503.